Agios Pharmaceuticals Inc
NASDAQ:AGIO

Watchlist Manager
Agios Pharmaceuticals Inc Logo
Agios Pharmaceuticals Inc
NASDAQ:AGIO
Watchlist
Price: 35.2 USD -0.62% Market Closed
Market Cap: 2B USD
Have any thoughts about
Agios Pharmaceuticals Inc?
Write Note

Agios Pharmaceuticals Inc
Treasury Stock

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Agios Pharmaceuticals Inc
Treasury Stock Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Treasury Stock CAGR 3Y CAGR 5Y CAGR 10Y
Agios Pharmaceuticals Inc
NASDAQ:AGIO
Treasury Stock
-$802.5m
CAGR 3-Years
-1%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Treasury Stock
-$7.8B
CAGR 3-Years
-37%
CAGR 5-Years
20%
CAGR 10-Years
-28%
Gilead Sciences Inc
NASDAQ:GILD
Treasury Stock
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Amgen Inc
NASDAQ:AMGN
Treasury Stock
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Treasury Stock
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Treasury Stock
-$14.2B
CAGR 3-Years
-24%
CAGR 5-Years
-96%
CAGR 10-Years
-78%
No Stocks Found

Agios Pharmaceuticals Inc
Glance View

Market Cap
2B USD
Industry
Biotechnology

Amid the thriving hub of biotechnology in Cambridge, Massachusetts, Agios Pharmaceuticals Inc. carved a niche for itself with a focused approach on rare and genetically defined diseases. From its inception, Agios set out to revolutionize the treatment landscape by diving into cellular metabolism's intricacies. This was a path less traveled, yet it held the potential to unlock therapies where few solutions previously existed. The company's initial explorations into cancer metabolism pioneered innovative treatments for various malignancies. However, the agility of Agios’s strategic vision was evident when it pivoted to concentrate its resources on the profound potential of precision medicines tailored for unheard-of-conditions like pyruvate kinase deficiency (PKD). To understand how Agios generates revenue, consider its commitment to harnessing deep scientific insights and translating them into impactful therapies. Agios’s revenue model involves the development and commercialization of pioneering therapies that address unmet medical needs, often collaborating with strategic partners to amplify its reach and efficacy in bringing these treatments to market. Moving beyond oncology, the firm now monetizes its research by focusing on a single area of expertise, shifting from developing cancer drugs to innovating within rare genetic disorders. This focused strategy is epitomized by their lead product for PKD, a chronic hemolytic anemia, leading to a revenue model intricately linked to their ability to develop and deliver highly specialized treatments that make a real-world impact on patient lives.

AGIO Intrinsic Value
18.78 USD
Overvaluation 47%
Intrinsic Value
Price

See Also

What is Agios Pharmaceuticals Inc's Treasury Stock?
Treasury Stock
-802.5m USD

Based on the financial report for Sep 30, 2024, Agios Pharmaceuticals Inc's Treasury Stock amounts to -802.5m USD.

What is Agios Pharmaceuticals Inc's Treasury Stock growth rate?
Treasury Stock CAGR 3Y
-1%

Over the last year, the Treasury Stock growth was 0%. The average annual Treasury Stock growth rates for Agios Pharmaceuticals Inc have been -1% over the past three years .

Back to Top